Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
agkistrodon acutus antivenin
- Development stage
- Unknown
- Lead developer
- Jiangxi Biological Products Research Institute
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Agkistrodon acutus antivenin is an equine-derived biologic therapeutic developed by Jiangxi Institute of Biological Products for the treatment of envenomation caused by bites from the Agkistrodon acutus (hundred-pace snake or five-pace viper). The antivenom consists of purified immunoglobulin antibodies or antibody fragments that specifically bind to and neutralize toxic components of the snake's venom, including hemorrhagic metalloproteinases, phospholipases A2, and enzymes that disrupt coagulation. By neutralizing these toxins, the antivenin prevents or mitigates severe clinical symptoms such as acute hemorrhage, edema, coagulopathy, and tissue necrosis. It is administered via intravenous infusion and has been evaluated in Phase 1 clinical trials to assess safety, pharmacokinetics, and immunogenicity in healthy volunteers.
- Other names
- Agkistodon acutus antiveninhundred-pace snake antiveninfive-pace viper antiveninDeinagkistrodon acutus antivenin
02
Targets
Acutolysin-AAaVMP (Agkistrodon acutus venom metalloproteinase)
Beyond the preview
Go deeper on agkistrodon acutus antivenin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on agkistrodon acutus antivenin.